Class action lawsuit filed against Inovio over misleading FDA approval prospects and delayed product submission.

A class action lawsuit has been filed against Inovio Pharmaceuticals and certain officers for allegedly making false and misleading statements about the FDA approval prospects and submission timeline of its lead product INO-3107. The lawsuit claims Inovio overstated the likelihood of accelerated FDA approval and failed to disclose manufacturing issues with its CELLECTRA device, causing delays in the Biologics License Application submission from mid-2024 to mid-2025. The revelations led to significant stock price drops, and the lawsuit seeks damages for investors who bought Inovio securities between October 2023 and December 2025. Investors have until April 7, 2026, to join the class action or seek lead plaintiff status.